The majority of laboratories measure total phenytoin concentration for therapeutic drug monitoring. However, there are substantial interindividual variations in free phenytoin concentrations, the pharmacologically active component.
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There is increasing interest in measuring free drug concentrations for a variety of substances, based on the principle that the free drug is the pharmacologically active component (1 ) . This is particularly true for phenytoin, which is highly bound to plasma protein (ϳ90%), producing a very small free fraction. The common laboratory practice is to measure total phenytoin concentrations, which assumes that phenytoin protein binding is relatively constant, so that the concentration of the active unbound drug can be predicted from the total drug plasma concentration (2, 3 ) . Despite the high percentage of protein binding, there can be substantial interindividual variation in free phenytoin concentrations, ranging from 9% to 25% (4 ) . The free drug fraction of phenytoin can be altered by various compounds and clinical situations, including hypoalbuminemia (5 ), uremia (6 ), pregnancy (7 ), critical illness (8 ) , HIV infection (9 ) , and administration of other drugs, including antiepileptic drugs (4, 10, 11 ) .
The potential for clinically significant discordance between free and total phenytoin concentrations exists for the above reasons. Several studies have addressed the correlation between total and free phenytoin (12, 13 ) , with earlier studies supporting a strong correlation between total and free phenytoin (4, 14 ) and more recent studies advocating free drug measurements (1, 10, 13 ) . Kilpatrick et al. (13 ) examined the association between free phenytoin and clinical status and found that in all patients the unbound concentration of phenytoin reflected the clinical status equally or better than the total phenytoin concentration.
Recognizing that free phenytoin concentrations are the most appropriate information for clinical use, this report describes the process and data we used to implement monitoring of free phenytoin only, replacing monitoring of total phenytoin, at an urban medical center.
Materials and Methods
Over a 6-week period, both total and free phenytoin concentrations were measured on every clinical phenytoin request sent to the toxicology laboratory at Hennepin County Medical Center, a 400-bed primary care, urban medical center. Total and free phenytoin measurements are were performed on the Hitachi 911 using the Cedia Phenytoin II assay (Boehringer Mannheim Systems). Ab-bott TDx free phenytoin calibrators at 0.0, 0.5, 1.0, 2.0, 3.0, and 4.0 mg/L were used.
Serum or plasma was obtained from whole blood collected in sodium EDTA, sodium heparin, or lithium heparin tubes. Samples were separated into total phenytoin and free phenytoin aliquots. Separation of free phenytoin and protein-bound phenytoin was achieved by filtering the sample through an anisotropic hydrophilic YMT ultrafiltration membrane (Millipore Corporation), using centrifugation at 1000g at 25°C for 20 min as the driving force for the ultrafiltration. The temperature of 25°C was chosen for separating the free fraction of phenytoin because at 25°C, 10% exists as the free fraction, compared with 15% at 37°C, when dissociation constants were studied in patient samples (15 ) . Thus, our medical center practice of using 10% as the reference for free phenytoin agrees with the literature.
The therapeutic total and free phenytoin concentrations used in our laboratory are 10 -20 mg/L and 1-2 mg/L, respectively (16 ) . These ranges have been verified using in-house data (data not shown) and are reported on the laboratory information system patient reports. Total imprecisions (CVs) for total phenytoin and free phenytoin at 24, 2.3, and 1.1 mg/L were 4.7%, 11%, and 22%, respectively. For patients whose percentage of free phenytoin was Ͼ12% or Ͻ8%, the medical record was reviewed, looking specifically at current medical conditions, current and recent medications, blood urea nitrogen, albumin, whether the patient was pregnant, and the patient's age.
Results
Over the 6-week period, 189 requests were received for phenytoin therapeutic drug monitoring on 139 patients (84 males, 55 females; age range, 7-77 years). Fifty-three patient data points were excluded from the study, leaving 136 patient data points (72%) for analysis. Reasons for data point exclusion included free phenytoin concentrations below the detection limit (0.5 mg/L), total phenytoin concentration Ͻ3 mg/L, and sample volume not sufficient for determination of both total and free phenytoin concentrations. The unbound phenytoin fractions were 6.8 -35.3% of the total phenytoin concentrations. Sixtyeight of the patient data points (50%) had a free phenytoin fraction (FPF) of 8 -12%, and 68 (50%) had a FPF outside of this range. Clinical history was available for 62 of the 68 patient data points for those patients whose FPF was Ͼ12% or Ͻ8%. Review of the medical records showed that 46 (74%) had an identifiable explanation or reason for this high or low FPF, leaving the remaining 16 (26%) with no identifiable cause for the abnormal FPF. Table 1 shows the incidence of clinical situations known to affect the FPF. Many patients had several reasons for increased or low FPF and were included in multiple categories. Hypoalbuminemia and valproic acid coadministration were the most common clinical situations associated with an abnormal FPF. Uremia, critical illness, and age extremes were also common clinical associations.
The clinical importance of the FPF became obvious when total phenytoin concentrations were compared with free phenytoin concentrations. For all patient data points, 56 (41%) had therapeutic total phenytoin concentrations, 32 (24%) had total phenytoin concentrations greater than therapeutic, and 48 (35%) had subtherapeutic total phenytoin concentrations. For the 56 patient data points with therapeutic total phenytoin concentrations, 5 had free phenytoin concentrations Ͼ2 mg/L and 3 had free phenytoin concentrations Ͻ1 mg/L. For the 32 patient data points with supratherapeutic total phenytoin concentrations, there were no subtherapeutic free phenytoin concentrations and 5 with therapeutic free phenytoin concentrations. The majority of the subtherapeutic total phenytoin patient data points had therapeutic free phenytoin concentrations (28 of 48).
The last two columns in Table 2 divide the patient data points into those with an FPF between 8% and 12% (group 1) and those with a FPF Ͻ8% or Ͼ12% (group 2). In group 1, 51% had both therapeutic total and free phenytoin concentrations (35 of 68). Two of 37 patient data points had subtherapeutic free phenytoin concentrations with therapeutic total concentrations, and 3 of 19 patient data points had therapeutic free concentrations with supratherapeutic total concentrations. Patient data points in When the concordance for all patient data points was compared, 95 of 136 (70%) of the free and total phenytoin concentrations were in agreement; i.e., both the free and the total phenytoin concentrations were supra-, sub-, or therapeutic. For those patient data points in group 1, 93% were concordant, whereas those in group 2 had only 47% concordant, leaving a majority of 53% discordant. These data were distributed to the hospital staff along with notification of plans to drop routine measurement of total phenytoin. The change was well accepted. Only two total phenytoin concentrations have been requested in the 5 months since the change was made.
Discussion
There is growing literature demonstrating that the relationship between free and total phenytoin concentrations is more unpredictable than previously thought. Kilpatrick et al. (13 ) reported a range of 6.7-33.3% free fraction, and Peterson et al. (4 ) reported a range of 9.7-24.7%. Our free fraction range of 6.8 -35.3% compares well to these previously published reports. However, 50% of our patient data points fell outside the 8 -12% range expected from review of the literature.
Several clinical conditions and medications are known to cause alterations in FPF. The majority of the patient data points in this study (74%) had an identifiable clinical diagnosis or concurrent drug therapy to account for an FPF outside the 8 -12% range. This leaves 26% of the patient data points for which the free, pharmacologically active fraction cannot be accurately predicted based on the total phenytoin concentration. Coadministration of valproic acid is a well-documented cause of altered phenytoin protein binding, but the FPF is not predictable (17 ) . Valproic acid coadministration was commonly associated with altered phenytoin binding in this study. In our patients, hypoalbuminemia accounted for the largest clinical diagnosis associated with an abnormal FPF. Even when albumin was within the reference range, there was an inverse relationship between the plasma albumin concentration and the unbound phenytoin fraction (13 ) , such that those patients with borderline albumin concentrations might not have predictable FPF.
One of the most striking findings of this study was the 30% overall rate of discordance between the total and free phenytoin concentrations (47% for group 2). Put another way, in 30% of patients on phenytoin therapy, the total phenytoin concentration was not accurately portraying the pharmacologically active component, free phenytoin concentration. This has serious implications for the management of epilepsy with phenytoin and for therapeutic drug monitoring of phenytoin. Phenytoin has a narrow therapeutic range, with potentially significant adverse events associated with under-or overmedicating a particular patient (18 ) . Additionally, our data show that even in patients without known causes of altered FPF, the free fraction cannot be predicted reliably based on the total phenytoin concentration.
On the basis of the evidence presented in this study, our clinical laboratory replaced total phenytoin measurements with free phenytoin measurements after this 6-week period of parallel free and total phenytoin concentration measurements. In the 5 months subsequent to this, only two total phenytoin measurements have been performed, one because of technician error and one in response to an unusual clinical situation. We postulate that in a given patient, the FPF fluctuates in comparison with the total phenytoin over time because of changes in the clinical status of the patient. Because we and the practitioners taking care of these patients cannot predict how a change in management or clinical status will affect the free and total phenytoin concentrations, we recommend measuring only free phenytoin in all patients. This has been widely accepted at our medical center, without reports of any adverse outcomes. In contrast, for example, before implementation of our free phenytoin only policy, four of our patients who had therapeutic total concentrations were found to have toxicity with free phenytoin concentrations Ͼ3.0 mg/L. Additionally, to identify those patients with normal vs abnormal binding fractions, both total and free phenytoin concentration measurements would have to be done on every new patient and at every point when the clinical status of the patient changed, to verify if the FPF had changed. In comparison, measuring only free phenytoin on all patients is much simpler, less costly than performing both the total and free measurements, and is a true measurement of the pharmacologically active drug. Therefore, we recommend free phenytoin concentration determinations for all therapeutic drug monitoring laboratories, with the elimination of total phenytoin determinations for routine practice.
Finally, we point out that the parameter "functional sensitivity", defined as an imprecision (CV) of 20%, has been proposed to serve as a clinically relevant estimate of the lowest reporting limit for an assay (19 ) . This parameter accounts for the imprecision associated with interassay variables, such as different calibration and reagent lots, and biological variables. A potential limitation of our findings could be attributed to our low-end CV of 22% at 1.1 mg/L, which falls above the 20% functional sensitivity required. Our patient groupings of data could possibly have been influenced, thus affecting our conclusions.
